Retatrutide TRIUMPH-1 Results: 28.3% at 80 Weeks and the FDA Filing Plan

Retatrutide remains investigational. TRIUMPH-1 reported 28.3% mean weight loss at 80 weeks under its efficacy analysis; 30.3% came from a selected 104-week extension.

Lilly plans a US BLA filing in Q1 2027, not a guaranteed approval date.

August 5, 20269 min read

By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.

Summarize this article with

Laboratory researcher wearing protective glasses and holding a vial

Retatrutide is an investigational weekly injection targeting GIP, GLP-1 and glucagon receptors.

TRIUMPH-1 reported 28.3% mean weight reduction at 80 weeks with 12 mg under its efficacy analysis, versus 25.0% under its treatment-regimen analysis.

The widely reported 30.3% result came from a selected 104-week extension, not the entire randomized population. Lilly's TRIUMPH-1 announcement explains the study and analyses.

Retatrutide is not FDA-approved. Lilly said on July 23, 2026 that it plans a Biologics License Application in Q1 2027.

That filing plan is not an approval or launch date. Expanded access is a restricted potential pathway for investigational treatment, not routine prescribing or a retail alternative.

Keep trial findings separate from treatment access

These drugs are still in trials. You can't get a prescription for them yet, so compare them with the medicines you can get today.

Explore the treatment pipeline →

How does retatrutide work?

Retatrutide is a single molecule designed to activate three hormone receptors: GIP, GLP-1 and glucagon.

It is being studied as a once-weekly subcutaneous injection. The original phase 2 report describes that receptor combination; Lilly's clinical-program announcement describes the conditions under investigation.

A receptor mechanism explains what researchers are testing.

It does not establish how much one person will lose, prove greater fat burning in everyday use or make a result directly comparable with another medicine's separate trial.

Retatrutide also does not share an approved prescribing label with Wegovy or Zepbound.

What did TRIUMPH-1 and TRIUMPH-4 find?

These were different trials, not a head-to-head comparison. TRIUMPH-1 studied 2,339 adults with obesity or overweight without diabetes over 80 weeks. TRIUMPH-4 studied 445 adults with obesity and knee osteoarthritis without diabetes over 68 weeks.

What did TRIUMPH-1 and TRIUMPH-4 find?
Study and populationResult and analysisImportant limit
TRIUMPH-1 main trial, 80 weeks12 mg: 28.3% mean weight reduction, efficacy estimand; 25.0%, treatment-regimen estimand. 9 mg: 25.9%, efficacy estimand.Both analyses come from a clinical trial; neither guarantees an individual's outcome.
TRIUMPH-1 selected extension, 104 weeks12 mg: 30.3% mean weight reduction, efficacy analysis.The extension enrolled 532 main-trial completers who tolerated assigned treatment and had baseline BMI at least 35. It was not the full randomized population.
TRIUMPH-4, obesity with knee osteoarthritis, 68 weeks12 mg: 28.7%; 9 mg: 26.4%; placebo: 2.1% mean weight reduction, efficacy estimand.A different population and duration from TRIUMPH-1, not evidence that one trial surpassed another.

The efficacy analysis estimates treatment use as intended. The treatment-regimen analysis includes outcomes regardless of stopping the assigned medicine. Selection for an extension changes who contributes to its result.

Comparing 30.3% from that selected extension with an unrelated drug's main trial would not establish a percentage improvement over the other medicine or equivalence with surgery.

What did the earlier phase 2 trial show?

The 2023 NEJM phase 2 trial randomized 338 adults with obesity, or overweight and a weight-related condition.

Its primary weight endpoint was at 24 weeks; the often-quoted figures below are the 48-week secondary endpoint. The 4 mg and 8 mg estimates combine their dose-escalation groups.

What did the earlier phase 2 trial show?
Assigned target doseMean weight reduction at 48 weeks
Placebo2.1%
1 mg8.7%
4 mg, combined groups17.1%
8 mg, combined groups22.8%
12 mg24.2%

In the 12 mg group, 100% achieved at least 5% weight reduction, 93% at least 10%, and 83% at least 15% at 48 weeks. Those responder rates describe that trial arm, not all 338 participants or a guarantee for future patients.

These results also do not establish a dosing recommendation.

What about sleep apnea, knee pain and diabetes?

Lilly's June 6, 2026 report describes nested knee-osteoarthritis and obstructive-sleep-apnea groups within TRIUMPH-1.

These results belong to that basket-trial design and its 80-week assessment, not automatically to TRIUMPH-4.

  • •In the sleep-apnea group, the sponsor reported an apnea-hypopnea index reduction of up to 36.1 events per hour, or 60.6%, from a baseline of 58.6. A reduction in the group average does not prove that most participants reached remission or a normal range.
  • •In the knee-osteoarthritis group, the sponsor reported pain-score improvement of up to 4.3 points, or 73.1%, from a baseline of 6.0. This is not an interchangeable result for a different trial or every patient with knee pain.
  • •Separately, TRANSCEND-T2D-1 enrolled 537 adults with type 2 diabetes managed with diet and exercise over 40 weeks. The efficacy analysis reported A1C reductions of up to 2.0 percentage points and mean weight reduction of up to 16.8%. These are a different population and duration from TRIUMPH-1.

Lilly subsequently announced TRIUMPH-2 and TRIUMPH-3 topline results in populations with type 2 diabetes or established cardiovascular disease.

The announcement says detailed results will be presented and published later. Results from one population should not be used as a promised outcome for another.

What side effects did TRIUMPH-1 report?

Use one trial and its own comparator when reading safety percentages.

The following rates come from Lilly's June 6 TRIUMPH-1 report, rather than combining retatrutide results with unrelated Wegovy trials.

What side effects did TRIUMPH-1 report?
Reported event in TRIUMPH-1Retatrutide 12 mgPlacebo
Nausea42.4%14.8%
Diarrhea32.0%13.5%
Constipation26.1%10.9%
Vomiting25.3%4.8%
Dysesthesia, abnormal skin sensations12.5%0.9%

Discontinuation because of adverse events in TRIUMPH-1 was 4.1%, 6.9% and 11.3% at the 4 mg, 9 mg and 12 mg doses, respectively, versus 4.9% with placebo. These are adverse-event discontinuations, not all-cause dropout rates.

A different titration schedule or population in another trial cannot, by itself, explain a difference in tolerability.

Dysesthesia was also reported in TRIUMPH-4, at 20.9% with 12 mg versus 0.7% with placebo in that study. That is not TRIUMPH-1's rate.

The reports do not establish that this event is unique to retatrutide or caused by a particular receptor, and they do not settle a future prescribing label or an individual's dose choice.

When could retatrutide be FDA-approved?

The verified next milestone is Lilly's planned US Biologics License Application in Q1 2027, announced July 23, 2026. Read the sponsor's filing statement.

A planned filing is not an accepted application, an FDA action date or an approval. It does not establish a commercial launch date or price.

Retatrutide remains investigational.

FDA states that it is not a component of an FDA-approved drug and cannot currently be used in compounding under federal law. FDA's unapproved-GLP-1 guidance is the relevant current US access warning, not a speculative approval countdown.

Does expanded access mean you can get retatrutide?

Not routinely. Lilly's NCT07629401 registry record describes individual-patient expanded access, first posted June 5, 2026 and last updated August 6.

The current record lists criteria; it is not an open retail prescription service.

The listed criteria include adults at least 18 with refractory BMI at least 35 despite the highest available weight-management therapy, at least two serious or life-threatening obesity-related complications, and inability to join a trial.

Standard options, including bariatric surgery, must have been discussed; contraindications can exclude a patient. This is a summary, not a complete eligibility assessment.

A treating clinician must assess whether a physician-initiated request is appropriate. The registry says availability depends on geography, supply and individual assessment.

FDA describes expanded access as a potential pathway for investigational treatment, not a guarantee that a sponsor or the agency will accept a request.

What did the classification lawsuit actually decide?

The amended district-court order dated October 3, 2025, in Lilly v.

FDA, upheld FDA's protein interpretation but sent its reasoning about analogous products back for reconsideration.

The order did not require a particular classification outcome or establish that retatrutide could later be compounded.

That historical order is not a statement of the current appeal or docket status. Nor does Lilly's later BLA filing plan, by itself, prove a final agency classification decision.

FDA's current position remains that retatrutide cannot be used in compounding under federal law.

A future shortage or classification label would not automatically satisfy all the conditions for lawful compounding. FDA explains the limits of compounding exemptions.

What is a useful next step now?

Trial headlines do not determine whether you should start, stop, switch or wait for treatment. Discuss current options with a clinician who knows your history.

Our pipeline overview and CagriSema guide explain other development programs without treating unlike trial percentages as a ranking.

Medical information:

This is source-based information, not medical advice, personal treatment experience or an approved retatrutide dosing guide.

Sources

Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.

Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.

Independent Clinical Perspective

What the doctors say

Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.

“Patients on both medications experienced substantial weight loss, and we observed no difference in the risk of gastrointestinal adverse events. In addition to effectiveness, factors like medication availability and insurance coverage will likely play a role in deciding which medication to initiate.”
Nicholas L. Stucky, MD, PhD, physician; co-author, real-world tirzepatide vs semaglutide study
Truveta Research / Providence Portland Medical Center
On real-world findings that practical factors matter beyond raw efficacy.
“For more than a million people at high risk of heart attack and stroke, this treatment on the NHS could be life-changing: offering a powerful new way to protect their hearts and improve their health.”
Helen Williams, Consultant pharmacist; National Clinical Director for Cardiovascular Disease Prevention
NHS England
NHS England announcing semaglutide (Wegovy) availability to cut heart attack and stroke risk.
NHS England ↗ · Apr 2026
“So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales. They are now considered important medicines for preventing deadly heart attacks and strokes. Today's guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers.”
Sonya Babu-Narayan, Consultant cardiologist; Clinical Director, British Heart Foundation
British Heart Foundation
British Heart Foundation reacting to NICE recommending semaglutide for cardiovascular event prevention.

Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.